Immune thrombocytopenia and b-cell-activating factor/a proliferation-inducing ligand

Seminars in Hematology

Volumn 50, Issue SUPPL.1, 2013, Pages

  Liu, Xin Guang ^a   Hou, Ming ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; ATACICEPT; AZATHIOPRINE; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; CORTICOSTEROID; DEXAMETHASONE; GLUCOCORTICOID; IMMUNOGLOBULIN; METHOTREXATE; PLACEBO; PREDNISONE; RITUXIMAB; TABALUMAB; THROMBOCYTE ANTIBODY; TOLL LIKE RECEPTOR 7; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CYTOKINE RELEASE; DENDRITIC CELL; DRUG DOSE REDUCTION; DRUG MEGADOSE; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOLOGICAL TOLERANCE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; SPLENECTOMY; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; THROMBOCYTE COUNT;

B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; CELL GROWTH PROCESSES; HUMANS; LIGANDS; THROMBOCYTOPENIA;

EID: 84877665011     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2013.03.021     Document Type: Article

References (130)

1. Berchtold P., Wenger M. Autoantibodies against platelet glycoproteins in autoimmune thrombocytopenic purpura: their clinical significance and response to treatment. Blood 1993, 81:1246-1250.
2. Cines D.B., Bussel J.B., Liebman H.A., Luning Prak E.T. The ITP syndrome: pathogenic and clinical diversity. Blood 2009, 113:6511-6521.
3. Chang M., Nakagawa P.A., Williams S.A., et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003, 102:887-895.
4. McMillan R., Wang L., Tomer A., Nichol J., Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004, 103:1364-1369.
5. Yang L., Wang L., Zhao C.H., et al. Contributions of TRAIL-mediated megakaryocyte apoptosis to impaired megakaryocyte and platelet production in immune thrombocytopenia. Blood 2010, 116:4307-4316.
6. Olsson B., Andersson P.O., Jernas M., et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003, 9:1123-1124.
7. Zhang F., Chu X., Wang L., et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol 2006, 76:427-431.
8. Stasi R., Pagano A., Stipa E., Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001, 98:952-957.
9. Provan D, Butler T, Evangelista ML, Amadori S, Newland AC, Stasi R. Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica. 2007;92:1695-1698.
10. Zaja F., Baccarani M., Mazza P., et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood 2010, 115:2755-2762.
11. Mukhopadhyay A., Ni J., Zhai Y., Yu G.L., Aggarwal B.B. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase. J Biol Chem 1999, 274:15978-15981.
12. Moore P.A., Belvedere O., Orr A., et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 1999, 285:260-263.
13. Schneider P., MacKay F., Steiner V., et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999, 189:1747-1756.
14. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004, 20:785-798.
15. Seyler T.M., Park Y.W., Takemura S., et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005, 115:3083-3092.
16. Cheema G.S., Roschke V., Hilbert D.M., Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001, 44:1313-1319.
17. Tan S.M., Xu D., Roschke V., et al. Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 2003, 48:982-992.
18. Nagatani K., Itoh K., Nakajima K., et al. Rheumatoid arthritis fibroblast-like synoviocytes express BCMA and are stimulated by APRIL. Arthritis Rheum 2007, 56:3554-3563.
19. Zhang J., Roschke V., Baker K.P., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001, 166:6-10.
20. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003, 48:3475-3486.
21. Groom J., Kalled S.L., Cutler A.H., et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002, 109:59-68.
22. Szodoray P., Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjogren's syndrome. Scand J Immunol 2005, 62:421-428.
23. Emmerich F., Bal G., Barakat A., et al. High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. Br J Haematol 2007, 136:309-314.
24. Zhou Z., Chen Z., Li H., et al. BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity 2009, 42:112-119.
25. Zhu X.J., Shi Y., Sun J.Z., et al. High-dose dexamethasone inhibits BAFF expression in patients with immune thrombocytopenia. J Clin Immunol 2009, 29:603-610.
26. Gu D., Ge J., Du W., et al. Raised expression of APRIL in Chinese patients with immune thrombocytopenia and its clinical implications. Autoimmunity 2009, 42:692-698.
27. Bossen C., Schneider P.BAFF APRIL and their receptors: structure, function and signaling. Semin Immunol 2006, 18:263-275.
28. Gavin A.L., Ait-Azzouzene D., Ware C.F., Nemazee D. DeltaBAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF. J Biol Chem 2003, 278:38220-38228.
29. Gavin A.L., Duong B., Skog P., et al. deltaBAFF, a splice isoform of BAFF, opposes full-length BAFF activity in vivo in transgenic mouse models. J Immunol 2005, 175:319-328.
30. Pradet-Balade B., Medema J.P., Lopez-Fraga M., et al. An endogenous hybrid mRNA encodes TWE-PRIL, a functional cell surface TWEAK-APRIL fusion protein. EMBO J 2002, 21:5711-5720.
31. Kolfschoten G.M., Pradet-Balade B., Hahne M., Medema J.P. TWE-PRIL; a fusion protein of TWEAK and APRIL. Biochem Pharmacol 2003, 66:1427-1432.
32. Roschke V., Sosnovtseva S., Ward C.D., et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002, 169:4314-4321.
33. Dillon S.R., Harder B., Lewis K.B., et al. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis Res Ther 2010, 12:R48.
34. Smirnova A.S., Andrade-Oliveira V., Gerbase-DeLima M. Identification of new splice variants of the genes BAFF and BCMA. Mol Immunol 2008, 45:1179-1183.
35. Daridon C., Devauchelle V., Hutin P., et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007, 56:1134-1144.
36. Ingold K., Zumsteg A., Tardivel A., et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005, 201:1375-1383.
37. Mackay F., Leung H. The role of the BAFF/APRIL system on T cell function. Semin Immunol 2006, 18:284-289.
38. Carter R.H., Zhao H., Liu X., et al. Expression and occupancy of BAFF-R on B cells in systemic lupus erythematosus. Arthritis Rheum 2005, 52:3943-3954.
39. Darce J.R., Arendt B.K., Wu X., Jelinek D.F. Regulated expression of BAFF-binding receptors during human B cell differentiation. J Immunol 2007, 179:7276-7286.
40. Chang S.K., Arendt B.K., Darce J.R., Wu X., Jelinek D.F. A role for BLyS in the activation of innate immune cells. Blood 2006, 108:2687-2694.
41. Tiegs S.L., Russell D.M., Nemazee D. Receptor editing in self-reactive bone marrow B cells. J Exp Med 1993, 177:1009-1020.
42. Gay D., Saunders T. Camper S, Weigert M. Receptor editing: an approach by autoreactive B cells to escape tolerance. J Exp Med 1993, 177:999-1008.
43. Pelanda R., Schwers S., Sonoda E., Torres R.M., Nemazee D., Rajewsky K. Receptor editing in a transgenic mouse model: site, efficiency, and role in B cell tolerance and antibody diversification. Immunity 1997, 7:765-775.
44. Halverson R., Torres R.M., Pelanda R. Receptor editing is the main mechanism of B cell tolerance toward membrane antigens. Nat Immunol 2004, 5:645-650.
45. Casellas R., Shih T.A., Kleinewietfeld M., et al. Contribution of receptor editing to the antibody repertoire. Science 2001, 291:1541-1544.
46. Fulcher D.A., Basten A. Whither the anergic B-cell?. Autoimmunity 1994, 19:135-140.
47. Tsuiji M., Yurasov S., Velinzon K., Thomas S., Nussenzweig M.C., Wardemann H. A checkpoint for autoreactivity in human IgM+ memory B cell development. J Exp Med 2006, 203:393-400.
48. Rathmell J.C., Cooke M.P., Ho W.Y., et al. CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 1995, 376:181-184.
49. Lang J., Arnold B., Hammerling G., et al. Enforced Bcl-2 expression inhibits antigen-mediated clonal elimination of peripheral B cells in an antigen dose-dependent manner and promotes receptor editing in autoreactive, immature B cells. J Exp Med 1997, 186:1513-1522.
50. Ota T., Aoki-Ota M., Tsunoda K., Nishikawa T., Koyasu S., Amagai M. Autoreactive B-cell elimination by pathogenic IgG specific for the same antigen: implications for peripheral tolerance. Int Immunol 2008, 20:1351-1360.
51. Seshasayee D., Valdez P., Yan M., Dixit V.M., Tumas D., Grewal I.S. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003, 18:279-288.
52. O'Connor B.P., Raman V.S., Erickson L.D., et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004, 199:91-98.
53. Binard A., Le Pottier L., Saraux A., Devauchelle-Pensec V., Pers J.O., Youinou P. Does the BAFF dysregulation play a major role in the pathogenesis of systemic lupus erythematosus?. J Autoimmun 2008, 30:63-67.
54. Craxton A., Draves K.E., Gruppi A., Clark E.A. BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway. J Exp Med 2005, 202:1363-1374.
55. Do R.K., Hatada E., Lee H., Tourigny M.R., Hilbert D., Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med 2000, 192:953-964.
56. Harless SM, Lentz VM, Sah AP, et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol. 2001;11:1986-9.
57. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 2002, 168:5993-5996.
58. Stadanlick J.E., Cancro M.P. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 2008, 20:158-161.
59. Enzler T., Bonizzi G., Silverman G.J., et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006, 25:403-415.
60. Ni C.Z., Oganesyan G., Welsh K., et al. Key molecular contacts promote recognition of the BAFF receptor by TNF receptor-associated factor 3: implications for intracellular signaling regulation. J Immunol 2004, 173:7394-7400.
61. Mecklenbrauker I., Kalled S.L., Leitges M., Mackay F., Tarakhovsky A. Regulation of B-cell survival by BAFF-dependent PKCdelta-mediated nuclear signalling. Nature 2004, 431:456-461.
62. Bossen C., Cachero T.G., Tardivel A., et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008, 111:1004-1012.
63. von Bulow G.U., van Deursen J.M., Bram R.J. Regulation of the T-independent humoral response by TACI. Immunity 2001, 14:573-582.
64. Shulga-Morskaya S., Dobles M., Walsh M.E., et al. B cell-activating factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004, 173:2331-2341.
65. Moisini I., Davidson A. BAFF: a local and systemic target in autoimmune diseases. Clin Exp Immunol 2009, 158:155-163.
66. Rahman Z.S., Rao S.P., Kalled S.L., Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003, 198:1157-1169.
67. Varfolomeev E., Kischkel F., Martin F., et al. APRIL-deficient mice have normal immune system development. Mol Cell Biol 2004, 24:997-1006.
68. Castigli E., Scott S., Dedeoglu F., et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci U S A 2004, 101:3903-3908.
69. Stein J.V., Lopez-Fraga M., Elustondo F.A., et al. APRIL modulates B and T cell immunity. J Clin Invest 2002, 109:1587-1598.
70. Planelles L., Carvalho-Pinto C.E., Hardenberg G., et al. APRIL promotes B-1 cell-associated neoplasm. Cancer Cell 2004, 6:399-408.
71. Castigli E., Wilson S.A., Scott S., et al. TACI and BAFF-R mediate isotype switching in B cells. J Exp Med 2005, 201:35-39.
72. Lai Kwan Lam Q., King Hung Ko O., Zheng B.J., Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci U S A 2008, 105:14993-14998.
73. Scapini P., Hu Y., Chu C.L., et al. Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice. J Exp Med 2010, 207:1757-1773.
74. Attanavanich K., Kearney J.F. Marginal zone, but not follicular B cells, are potent activators of naive CD4 T cells. J Immunol 2004, 172:803-811.
75. Chang S.K., Mihalcik S.A., Jelinek D.F. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 2008, 180:7394-7403.
76. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000, 404:995-999.
77. Mackay F., Woodcock S.A., Lawton P., et al. Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med 1999, 190:1697-1710.
78. Batten M., Fletcher C., Ng L.G., et al. TNF deficiency fails to protect BAFF transgenic mice against autoimmunity and reveals a predisposition to B cell lymphoma. J Immunol 2004, 172:812-822.
79. Zheng Y., Gallucci S., Gaughan J.P., Gross J.A., Monestier M. A role for B cell-activating factor of the TNF family in chemically induced autoimmunity. J Immunol 2005, 175:6163-6168.
80. Kayagaki N., Yan M., Seshasayee D., et al. BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2. Immunity 2002, 17:515-524.
81. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003, 62:168-171.
82. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 2006, 54:192-201.
83. Krumbholz M., Specks U., Wick M., Kalled S.L., Jenne D., Meinl E. BAFF is elevated in serum of patients with Wegener's granulomatosis. J Autoimmun 2005, 25:298-302.
84. Kim J.Y., Yang Y., Moon J.S., et al. Serum BAFF expression in patients with myasthenia gravis. J Neuroimmunol 2008, 199:151-154.
85. Fabris M., Quartuccio L., Sacco S., et al. B-Lymphocyte stimulator (BLyS) up-regulation in mixed cryoglobulinaemia syndrome and hepatitis-C virus infection. Rheumatology (Oxford) 2007, 46:37-43.
86. Fabris M., Visentini D., De V., et al. Elevated B cell-activating factor of the tumour necrosis factor family in coeliac disease. Scand J Gastroenterol 2007, 42:1434-1439.
87. Migita K., Abiru S., Maeda Y., et al. Elevated serum BAFF levels in patients with autoimmune hepatitis. Hum Immunol 2007, 68:586-591.
88. Migita K., Ilyassova B., Kovzel E.F., et al. Serum BAFF and APRIL levels in patients with PBC. Clin Immunol 2010, 134:217-225.
89. Krumbholz M., Theil D., Derfuss T., et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005, 201:195-200.
90. Asashima N., Fujimoto M., Watanabe R., et al. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris. Br J Dermatol 2006, 155:330-336.
91. Matsushita T., Hasegawa M., Matsushita Y., et al. Elevated serum BAFF levels in patients with localized scleroderma in contrast to other organ-specific autoimmune diseases. Exp Dermatol 2007, 16:87-93.
92. Koyama T., Tsukamoto H., Masumoto K., et al. A novel polymorphism of the human APRIL gene is associated with systemic lupus erythematosus. Rheumatology (Oxford) 2003, 42:980-985.
93. Koyama T., Tsukamoto H., Miyagi Y., et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. Ann Rheum Dis 2005, 64:1065-1067.
94. Stohl W., Metyas S., Tan SM, et al. Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 2004, 63:1096-1103.
95. Ramanujam M., Bethunaickan R., Huang W., Tao H., Madaio M.P., Davidson A. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010, 62:1457-1468.
96. Ramanujam M., Wang X., Huang W., et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004, 173:3524-3534.
97. Ramanujam M., Wang X., Huang W., et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006, 116:724-734.
98. Liu W., Szalai A., Zhao L., et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 2004, 50:1884-1896.
99. Baker K.P., Edwards B.M., Main S.H., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48:3253-3265.
100. McKay J C-SH, Boling E, Valente R, Limanni A, Racewicz A, Wierzbinska-Zarowny D, Fernandez V, Zhong J, Zilberstein M, Freimuth W. LBRZ01 Study Group. Belimumab, a fully human monoclonal antibody to B-lymphocyte stimulator (BLyS), combined with standard of care therapy reduces the signs and symptoms of rheumatoid arthritis in a heterogeneous subject population. Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals. 2005:Oral Presentation 1920.
101. Tak P.P., Thurlings R.M., Rossier C., et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008, 58:61-72.
102. Genovese M.C.M.E., Biagini M., Bojin S., Sloan-Lancaster J. Phase 2 study of safety and efficacy of a novel anti-BAFF monoclonal antibody, in patients with RA treated with methotrexate (MTX). Arthritis Rheum 2009, 60(Suppl 10):1923.
103. Thangarajh M., Gomes A., Masterman T., Hillert J., Hjelmstrom P. Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis. J Neuroimmunol 2004, 152:183-190.
104. Huntington N.D., Tomioka R., Clavarino C., et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006, 18:1473-1485.
105. Hartung H.P., Kieseier B.C. Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord 2010, 3:205-216.
106. Furie R., Stohl W., Ginzler E.M., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10:R109.
107. Chatham W.F.R., Petri M., Ginzler E.M., Wallache D.J., Stohl W., Strand V. Belimumab (FULLY HUMAN MONOCLONAL ANTIBODY to BLyS) improved or stabilized systemic lupus erythematosus (SLE) disease activity over 3 years of therapy. Arthritis Rheum 2008, 58:S573-S574.
108. Wallace D.J., Stohl W., Furie R.A., et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61:1168-1178.
109. Navarra S.V., Guzman R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377:721-731.
110. Furie R., Petri M., Zamani O., et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63:3918-3930.
111. Olsson B., Andersson P.O., Jacobsson S., Carlsson L., Wadenvik H. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005, 93:139-144.
112. Panitsas F.P., Theodoropoulou M., Kouraklis A., et al. Adult chronic idiopathic thrombocytopenic purpura (ITP) is the manifestation of a type-1 polarized immune response. Blood 2004, 103:2645-2647.
113. Chow L., Aslam R., Speck E.R., et al. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell-mediated responses that are differentially sensitive to therapy. Blood 2010, 115:1247-1253.
114. Stasi R., Cooper N., Del Poeta G., et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008, 112:1147-1150.
115. Kawasaki A., Tsuchiya N., Fukazawa T., Hashimoto H., Tokunaga K. Analysis on the association of human BLYS (BAFF, TNFSF13B) polymorphisms with systemic lupus erythematosus and rheumatoid arthritis. Genes Immun 2002, 3:424-429.
116. Novak A.J., Grote D.M., Ziesmer S.C., et al. Elevated serum B-lymphocyte stimulator levels in patients with familial lymphoproliferative disorders. J Clin Oncol 2006, 24:983-987.
117. Zhu X.J., Shi Y., Peng J., et al. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia. Blood 2009, 114:5362-5367.
118. Yu H., Liu Y., Han J., et al. TLR7 regulates dendritic cell-dependent B-cell responses through BlyS in immune thrombocytopenic purpura. Eur J Haematol 2011, 86:67-74.
119. Yujiri T., Tanaka Y., Tanaka M., Takahashi T., Tanizawa Y. Alteration in serum B cell-activating factor levels inpatients with idiopathic thrombocytopenic purpura after Helicobacter pylori eradication therapy. Br J Haematol 2011, 152:496-498.
120. Zhou Z., Li X., Li J., et al. Direct B-cell stimulation by peripheral blood monocyte-derived dendritic cells in idiopathic thrombocytopenic purpura patients. J Clin Immunol 2010, 30:814-822.
121. Tomai M.A., Imbertson L.M., Stanczak T.L., Tygrett L.T., Waldschmidt T.J. The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol 2000, 203:55-65.
122. Glaum M.C., Narula S., Song D., et al. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J Allergy Clin Immunol 2009, 123:224-230.
123. Yang Q., Xu S., Li X., et al. Pathway of Toll-like receptor 7/B cell activating factor/B cell activating factor receptor plays a role in immune thrombocytopenia in vivo. PLoS One 2011, 6:e22708.
124. Steer J.H., Kroeger K.M., Abraham L.J., Joyce D.A. Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. J Biol Chem 2000, 275:18432-18440.
125. Guo C., Chu X., Shi Y., et al. Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura. J Clin Immunol 2007, 27:557-562.
126. Mackay F., Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003, 14:311-324.
127. Scapini P., Bazzoni F., Cassatella M.A. Regulation of B-cell-activating factor (BAFF)/B lymphocyte stimulator (BLyS) expression in human neutrophils. Immunol Lett 2008, 116:1-6.
128. Pillai S., Mattoo H., Cariappa A. B cells and autoimmunity. Curr Opin Immunol 2011, 23:721-731.
129. Provan D., Stasi R., Newland A.C., et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood 2010, 115:168-186.
130. Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Jr, Crowther MA. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia Blood2011;117:4190-4207.